AIM-HIV PROJECT------------------------Instituto Salud Carlos III
home

AIM-HIV NEWS

 

July 19-22, 2015

ISCIII and SEPROX presented a poster at the 8th IAS Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2015) held in Vancouver, Canada (www.ias2015.org). Most recent results about the anti-HIV-1 activity of 5HT were presented. 

201507 IAS2015 Poster

International AIDS Society


June 18, 2015

A meeting was held in Brussels, where partners of projects funded by the European Commission (EC) and focused on microbicides (AIM-HIV, CHAARM and MOTIF) summarized their achievements. Members of the EC and other stakeholders, like the International Partnership for Microbicides (IPM) and the European & Developing Countries Clinical Trials Partnership (EDCTP), participated in this event aim to review how to go ahead with the results generated by these projects.  


May 6-8, 2015

ISCIII and SEPROX presented a poster at the XVII Congreso Nacional sobre el Sida (www.congresonacionalsida.es) in San Sebastián, Spain, about the anti-HIV properties of 5HT in vitro.  

201505 XVII Congreso Nacional sobre el Sida e ITS Poster

logo-web-congreso-sida


December 2, 2014 

The Final meeting was held in the facilities of CEA, in Paris, with the participation of all the partners. In the meeting, the work and  time line were reviewed, taking into account the 6 months extension of the project. 


October 28-31, 2014

ISCIII and SEPROX presented a poster at the HIV Research for Prevention (HIVR4P) Conference (hivr4p.org) held in Cape Town, South Africa, with new results about the antiviral activity of 5-hydroxytyrosol. In addition, USR, SEPROX and ISCIII presented another poster about the inhibition of productive R5 HIV-1 infection in human cervical tissue explants by 5HT. 

201410 HIVR4P Poster

HIV-R4P-dated-logo


January 10, 2014

The Progress Meeting of the project was held in Madrid and counted on the participation of the partners of the project and the Scientific Advisory Board (SAB). After the meeting the SAB wrote up a document of recommendations.

Members of the SAB:

‐ Professor Robin Shattock. Imperial College London

‐ Professor Anna‐Lena Spetz. Karolinska Institutet, Stockholm

‐ Professor Clara Menéndez. CRESIB, Barcelona

‐ Dr Felipe García. Hospital Clínic. Barcelona

‐ Dr Jose María Gatell. Hospital Clínic. Barcelona


October 7-10, 2013

ISCIII and SEPROX have presented an oral communication and a poster in the AIDS Vaccine Conference 2013 held in Barcelona. The title was "Antiviral activity of 5-Hidroxytyrosol, a microbicidal candidate".

http://www.vaccineenterprise.org/conference/2013/

201310 AIDS Vaccine Conference 2013 Poster.pdf


June 30 - July 3, 2013

ISCIII and SEPROX presented a poster in the 7th IAS Conference on HIV Pathogenesis, Treatment and Prevention held in Kuala Lumpur, Malaysia. The title of the poster was "Antiviral activity of 5-Hidroxytyrosol, a microbicidal candidate". 

http://www.ias2013.org/ 

20130630_7th IAS conference_póster.pdf

International AIDS Society


January 28, 2013

AIM-HIV starts officially the 1st December. KickOff meeting was held in Madrid 30-31 January 2013.


July 10, 2012 

Press conference for the presentation of the AIM-HIV project. Dr José Alcami and Dr Eduardo Gomez-Acebo have participated in the press conference held at Instituto de Salud Carlos III to present the AIM-HIV project that has been recently approved by the European Commission.
ISCIII SITE // DOWNLOAD PDF

 

 

NEWS 01  

        

Productive HIV-1 infection of human cervical tissue ex vivo is associated with the secretory phase of menstrual cycle. Read more.    

  

NEWS 02

    

10/01/2014. The partners of the project and the Scientific Advisory Board attended the Progress Meeting of the project in Madrid.  

NEWS 03

   

October 7-10, 2013. ISCIII and SEPROX presented an oral communication and a poster in the AIDS Vaccine Conference. Read more.

 

Instituto de Salud Carlos III. 2013. All rights reserved

This project has received funding from the European Union’s Seventh Framework Programme for research, technological development and demonstration under grant agreement no 305938.

Web Map  Legal AdviceAccesibility | Contact

cea unisr seprox biotech IscIII